Saving More Lives
Moffitt Cancer Center's unparalleled research focuses on leading-edge discoveries that are rapidly translated into improved diagnostic, preventative, and therapeutic advancements, which are then shared with providers throughout the state and the country.
As Florida’s first National Cancer Institute-designated Comprehensive Cancer Center and one of only 30 leading cancer centers in the U.S. participating in the National Comprehensive Cancer Network, Moffitt is at the very forefront of cancer centers worldwide.
Equipped with top research and care experts working side-by-side, Moffitt is uniquely positioned to revolutionize cancer treatment, elevate care and save more lives.
A Beacon for Cancer Care in FL
-
67 Counties Served
In the last year, Moffitt has served patients from all 67 of Florida's counties. We've seen patients from all 50 states and 130+ countries.
-
20,000+
Patients participated in clinical trials and nontherapeutic studies last year.
-
758
Unique articles published by Moffitt physicians & scientists last year.
-
31
Investigative new drug applications submitted to the FDA in the past year.
-
28
U.S. patents issued in the past year.
Superior Cancer Survival Rates
Moffitt is proud of the survival rates we deliver for cancer patients in Florida. Our outcome statistics are derived from The Surveillance, Epidemiology, and End Results (SEER) Program, a trusted source supported by the National Cancer Institute’s Division of Cancer Control and Population Sciences.
- Bladder Cancer - 157% Higher Survival Rates
- Breast Cancer - 50% Higher Survival Rates
- Colorectal Cancer - 119% Higher Survival Rates
- Gallbladder Cancer - 234% Higher Survival Rates
- Liver Cancer - 53% Higher Survival Rates
- Lung Cancer - 100% Higher Survival Rates
- Melanoma - 59% Higher Survival Rates
- Mesothelioma - 91% Higher Survival Rates
- Ovarian Cancer - 28% Higher Survival Rates
- Pancreatic Cancer - 283% Higher Survival Rates
- Prostate Cancer - 45% Higher Survival Rates
- Stomach Cancer - 81% Higher Survival Rates
Food as Medicine
Revolutionary advances in our understanding of cancer biology and metabolism have fueled new research on the role of diet to help prevent cancer, make cancer treatments work better, and reduce treatment toxicity.
With a $10 million investment in the Population Engagement and Research Lab (PEARL), Moffitt is conducting nutritional, metabolomic, and behavioral studies overseen by talented scientists with expertise in energy balance and cancer metabolism. One of only three such facilities in the nation, PEARL is equipped with a research kitchen to enable precision feeding studies which allow investigators to understand how specific diets impact specific drivers of cancer.
Improving Cancer Outcomes with Diet
Highlights from the current research portfolio:
- Green tea catechins to fight prostate cancer (clinical trial)
- DINING study to evaluate an anti-inflammatory diet for colorectal cancer prevention
- Evaluate the effects of two-week ketogenic diet on immune function to improve the efficacy of CAR T-cell therapy (pilot clinical trial)
- Effects of ketogenic diet on efficacy of immune checkpoint inhibitor therapy (pilot clinical trial)
- Effects of fermented foods on the gut microbiome and treatment response in colorectal and lung cancer patients (pilot clinical trial)
- A clinical trial of an easy-to-swallow, high protein, meal-replacement for head and neck cancer patients
- MIND-BC trial to evaluate whether a Mediterranean DASH diet can improve cognitive function after chemotherapy in breast cancer survivors
- The Moffitt Table™ cookbook, which contains nutrient-dense meals that are both preventative and beneficial for people diagnosed with cancer
Clinical Care Often Starts in a Lab
Learn about a few of the departments who are conducting studies that will change the way patient care is delivered in the future.
High Volume Fosters High Expertise
Our multispecialty medical professionals are dedicated to the treatment and research of cancer, and cancer only. By tailoring individualized care plans to unique patient needs, Moffitt is aiming to achieve the best outcome for each patient to save more lives. In the past year Moffitt saw:
-
713,000+
Outpatient Visits
-
102,000+
Unique Patients Seen
-
14,000+
Surgical Cases
-
31,000+
New Patients
Delivering Breakthroughs to Patients First
Moffitt’s unparalleled research focuses on leading-edge discoveries that can rapidly translate into improved diagnostic, preventative and therapeutic advancements. Recent major scientific breakthroughs include:
-
Moffitt Pioneers Immune Cell Therapy for Breast Cancer Leptomeningeal Disease
Moffitt Cancer Center is investigating the use of a dendritic cell vaccine created from patients’ own immune cells to treat leptomeningeal disease (LMD) in breast cancer. In a first-in-human phase 1 trial, patients with HER2-positive or triple-negative breast cancer receive intrathecal (spinal fluid) injections of the vaccine, which so far has shown promising results with good tolerance and prolonged survival in some cases. This innovative approach offers hope for a disease with historically poor outcomes and virtually no other effective treatments.
-
FDA Approved New Low-Toxicity AlloHSCT Regimen for AML Patients
A newly FDA-approved combination of treosulfan and fludarabine is now available as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in acute myeloid leukemia (AML) patients at Moffitt Cancer Center. This treatment option is noted for its low toxicity, offering AML patients a safer pathway to stem cell transplant, which is an essential step for achieving lasting remission. The approval provides clinicians with an improved approach for treating high-risk or relapsed AML, enhancing patient outcomes and care at Moffitt.
-
Moffitt Launches Clinical Trial to Overcome Bloodbrain Barrier in Glioblastoma
Moffitt Cancer Center is leading a Phase 3 trial using Carthera's SonoCloud-9, an implantable ultrasound device that opens the blood-brain barrier to enhance chemotherapy delivery in recurrent glioblastoma. This technology may allow drugs like carboplatin to reach tumors more effectively, addressing a major hurdle in brain cancer treatment. The trial offers hope for improved outcomes in a disease where existing therapies have struggled to extend survival.
-
Leader for Cell & Targeted Therapies
Cellular immunotherapy is an innovative treatment approach that harnesses the body's own immune system to fight cancer. At Moffitt, we offer several types of cellular immunotherapy, including CAR T-cell therapy, TCR therapy and TIL therapy.
These novel treatments are helping transform the landscape for many current and future cancer patients. Moffitt is the first cancer treatment center in the world to have treated nearly 2,000 patients with CAR-T therapy. The program also recently reached a major milestone with more than 10,000 blood and marrow transplants performed.
-
First to Introduce Proteus®ONE Proton Therapy System to Tampa Bay
Moffitt’s therapy system, supplied by IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, is the world's most advanced form of cancer-killing technology. Moffitt will be one of the few top cancer centers in the U.S. with state-of-the-art proton therapy technology that has received clearance from the Food and Drug Administration. This positions Moffitt at the forefront of cancer care and offers patients access to highly effective minimally invasive treatments and produce better outcomes.
Attracting Top Talent to Florida
-
~10,000
Team Members
-
400+
Physician Faculty Members
-
190+
Research Faculty
-
440+
Advanced Practice Providers
Moffitt has almost 10,000 team members living and working in Tampa Bay and across Florida. Moffitt Medical Group is Florida’s largest multispecialty medical group practice dedicated to cancer treatment. With hundreds of board-certified physicians and advanced practice professionals who have dedicated their careers to cancer care, Moffitt providers are uniquely trained in cancer and bring exceptional expertise from treating a high volume of complex cases.
As one of the nation's top-ranked cancer hospitals, Moffitt attracts highly qualified healthcare providers and researchers. The number of providers employed at Moffitt has grown by 40% in the past five years. Many of our oncologists are physician scientists, conducting research to develop new and more effective therapies to broaden the range of services we offer.
Teaching the Next Generation of Physicians and Scientists in Oncology
Education and training is a fundamental part of Moffitt's core mission. We provide numerous education opportunities for physicians and other healthcare professionals, international visiting scholars, postdoctoral, graduate and undergraduate college and pre-college students.
Moffitt is an ACGME- accredited institution and serves as an academic training affiliate of the University of South Florida Morsani College of Medicine. Moffitt's research enterprise offers training and education in numerous areas key in the fight against cancer including Postdoctoral Training, Graduate Training, Undergraduate and Visiting Scholars and Pre-College Programs.
In 2024, Moffitt trained over 500 medical students, 400 residents, and more than 200 oncology fellows.
-
550+
Research Trainees Last Year
-
1,200+
Graduate Medical Education Trainees Last Year
The End of Cancer Begins Here®
We've spent decades building the kind of enriched, collegial, and collaborative environment required to perform outstanding cancer research and educate the next generation. The Research Institute within Moffitt boasts five research programs, four centers of excellence, five research departments, 15 academic clinical departments, and even more divisions, each carrying out critical elements in the fight against cancer.
